BIRTH ASPHYXIA · NEONATAL ENCEPHALOPATHY · HYPOXIC-ISCHEMIC ENCEPHALOPATHY
A physician-led, laboratory-verified treatment programme targeting the neurological consequences of oxygen deprivation — designed to support motor development, cognitive recovery and neuroplasticity based on the individual injury pattern, age and clinical profile of each patient.
Request Medical ConsultationAbout the Condition
Hypoxic-ischemic brain injury (HIE) occurs when the brain is deprived of adequate oxygen and blood flow. The resulting cellular damage triggers a cascade of neuronal death, white matter injury and chronic neuroinflammation that can persist long after the initial insult.
In neonates, HIE is most commonly caused by birth asphyxia — complications during labour and delivery that interrupt placental blood flow. In older children and adults, cardiac arrest, near-drowning, severe hypotension or perioperative complications can produce the same pattern of injury.
HIE is an acute injury with chronic consequences. The severity depends on the duration and degree of oxygen deprivation, the brain regions affected, and the age at which the injury occurred. Earlier intervention generally produces better clinical outcomes — the developing brain retains significant neuroplastic potential that diminishes over time.
Neonatal HIE (Birth Asphyxia)
The most common form, resulting from oxygen deprivation during labour, delivery or the immediate postnatal period. Affects 1–3 per 1,000 live births in developed countries. Severity is graded using the Sarnat classification (mild, moderate, severe). Motor, cognitive and developmental consequences depend on the extent and location of brain injury.
Cardiac Arrest HIE
Occurs in children or adults following cardiac arrest with prolonged cerebral hypoperfusion. The duration of circulatory arrest is the primary determinant of injury severity. Global cerebral ischaemia typically affects the hippocampus, basal ganglia and cortical watershed zones. Recovery potential depends on the interval between arrest and restoration of circulation.
Near-Drowning HIE
Results from submersion injury with prolonged hypoxia. Predominantly affects paediatric patients. The injury pattern is similar to cardiac arrest HIE but often involves additional hypothermia-related factors. Younger patients may retain greater neuroplastic recovery potential.
Perioperative HIE
Occurs as a complication of surgical procedures — typically cardiac surgery, major vascular surgery or procedures requiring prolonged anaesthesia. The injury mechanism involves transient cerebral hypoperfusion during or immediately after the procedure. Severity varies from focal deficits to diffuse cortical injury.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates the nature and timing of the hypoxic-ischemic event, current neurological status, imaging findings and developmental trajectory.
We do not offer a cure for established brain injury. Our programme targets the biological mechanisms that limit recovery — chronic neuroinflammation, impaired myelination and ongoing secondary damage — with the clinical objective of supporting neuroplasticity, motor development and functional improvement.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2016 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
32
HIE patients treated
72%
demonstrated measurable functional improvement within 3–6 months
66%
showed improvement in at least one motor milestone
59%
demonstrated improved cognitive engagement and responsiveness
53%
achieved clinically meaningful reduction in spasticity
68%
maintained continued functional gains — follow-up to 3 years
Improved head and trunk control
69%
Increased voluntary limb movement and reaching
63%
Improved feeding and oral motor function
56%
Enhanced visual tracking and cognitive responsiveness
61%
Reduction in pathological muscle tone and spasticity
53%
2–6 weeks
Initial functional response
3–6 months
Clinically meaningful change
1–3 years under continued monitoring
Continued improvement and developmental gains
Important: Outcomes depend on the severity and timing of the hypoxic-ischemic event, the patient's age, baseline neurological status and individual biological response. Earlier intervention generally correlates with better outcomes. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“Amir was eighteen months old and could not hold his head up. After the programme he started lifting it on his own during tummy time. His physiotherapist confirmed the change. Tone in his neck and trunk had improved. The gap between him and other children his age is closing rather than widening, and that distinction matters enormously to us.”
Patient's mother
Neonatal HIE (birth asphyxia) · UAE
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our HIE programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's injury pattern, developmental status, age and clinical priorities.
No surgery required
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
Particularly important in paediatric HIE patients, where repeated anaesthesia exposure carries additional neurodevelopmental risks.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient's own cells. Zero risk of graft-versus-host disease with autologous protocols. Allogeneic options are available when autologous collection is not feasible.
Targets the biological mechanisms limiting recovery
Our protocol addresses chronic neuroinflammation, impaired myelination, excitotoxicity and oxidative stress — the persistent biological barriers to neurological recovery after hypoxic-ischemic injury.
Complements existing rehabilitation
Our programme works alongside ongoing physiotherapy, occupational therapy and developmental interventions. Patients do not need to discontinue any existing rehabilitation or medication.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient's location anywhere in the world. For families with severely affected children where long-distance travel is difficult, this removes a major barrier to accessing care.
What It Is
MSCs are multipotent regenerative cells with established neuroprotective and immunomodulatory properties. They are among the most extensively studied cell types in regenerative neurology and have demonstrated safety across thousands of clinical applications worldwide, including paediatric populations.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous) or sourced from a certified donor (allogeneic), depending on the patient's age and clinical indications. In paediatric cases, allogeneic sources are often preferred to avoid invasive collection in young children. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Hypoxic-Ischemic Brain Injury
Following hypoxic-ischemic injury, a prolonged secondary inflammatory cascade continues to damage surviving neurons and oligodendrocytes for weeks to months after the initial event. MSCs address this mechanism directly — suppressing the inflammatory response, protecting vulnerable cells and creating biological conditions that support the brain's endogenous repair processes.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific injury pattern, neurological status, age, biological markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess the nature and timing of the hypoxic-ischemic event, current neurological status, imaging findings and developmental trajectory. This consultation is free and carries no obligation.
A detailed review of all medical documentation — including MRI findings, developmental assessments and rehabilitation records. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme. Where clinically appropriate, our medical board may approve a travelling treatment programme — our medical team flies directly to the patient.
Structured rehabilitation sessions with our specialist, adapted to the patient's age, injury pattern and current functional level. Paediatric protocols incorporate developmental milestones and age-appropriate therapeutic approaches. Available at our clinic or remotely coordinated with your local medical team.
Your dedicated coordinator monitors neurological status, developmental progress and overall well-being. A medical-grade wearable bracelet supports continuous health tracking regardless of your location. Follow-up assessments are scheduled at regular intervals to document progress and guide ongoing care.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by both paediatric and adult HIE patients.
Temporary mild reactions — such as transient low-grade temperature, slight irritability in young children or mild fatigue — may occur in a minority of patients. These are typically short-lived and indicate active biological engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including seizure activity or acute illness — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Uncontrolled epileptic status (active seizure disorder must be stabilised prior to treatment)
Post-Treatment
Dedicated rehabilitation specialist
monitors motor development, cognitive milestones and overall neurological status
Personalised rehabilitation programme
adapted to the patient's age, injury pattern and current developmental stage
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Neurological recovery after hypoxic-ischemic injury follows a non-linear trajectory. Biological repair processes — remyelination, synaptic reorganisation, resolution of chronic inflammation — require sustained clinical oversight. The post-treatment period is integral to the therapeutic programme.
Get Started
If your child or someone you love has been diagnosed with hypoxic-ischemic brain injury, our medical team is available for a free, no-obligation medical consultation — based on the diagnosis, current neurological status and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
